Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving viable micro-organism
Reexamination Certificate
2006-04-11
2006-04-11
Leary, Louise N. (Department: 1655)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving viable micro-organism
C435S029000, C435S004000, C435S015000, C435S016000, C435S023000, C435S024000
Reexamination Certificate
active
07026136
ABSTRACT:
The instant methods and compositions represent an advance in controlling drug resistance in microbes. AcrAB-like efflux pumps have been found to control resistance to drugs, even in highly resistant microbes. Accordingly, methods of treating infection, methods of screening for inhibitors of AcrAB-like efflux pumps, and methods of enhancing antimicrobial activity of drugs are provided. Pharmaceutical composition comprising an inhibitor of an AcrAB-like efflux pump and an antimicrobial agent are also provided.
REFERENCES:
patent: 4806529 (1989-02-01), Levy
patent: 5021407 (1991-06-01), Levy
patent: 5064821 (1991-11-01), Levy
patent: 5179096 (1993-01-01), Gentilini et al.
patent: 5258372 (1993-11-01), Levy
patent: 5589470 (1996-12-01), Levy
patent: 5789188 (1998-08-01), Rothstein et al.
patent: 5811412 (1998-09-01), Levy
patent: 5817793 (1998-10-01), Levy
patent: 5989832 (1999-11-01), Trias et al.
patent: 6068972 (2000-05-01), Levy
patent: 6326391 (2001-12-01), Markham et al.
patent: 6346391 (2002-02-01), Oethinger et al.
patent: 6448006 (2002-09-01), Levy
patent: 6677133 (2004-01-01), Oethinger et al.
patent: WO 96/33285 (1996-10-01), None
patent: WO 99/37667 (1999-01-01), None
patent: WO 99/17607 (1999-04-01), None
patent: WO 99/17760 (1999-04-01), None
patent: WO 99/17791 (1999-04-01), None
patent: WO 99/32657 (1999-07-01), None
patent: WO 99/37800 (1999-07-01), None
patent: WO 00/01714 (2000-01-01), None
patent: WO 00/32196 (2000-06-01), None
patent: WO 96/23075 (2000-08-01), None
Aono, Rikizo (1998) “Improvement of Organic Solvent Tolerance Level ofEscherichia Coliby Overexpression of Stress-Responsive Genes”, Extremophiles vol. 2 p. 239-248.
Brenwald, N.P. et al.Fluoroquinolone Resistance inStreptococcus pneumoniaeby an Efflux Mechanism, Abstr of the 37thInersc. Conference on Antimicrobial Agents and Chemotherapy.
Buysse, J.M. et al. (1996) “Mutation of the AcrAB antibiotic efflux pump inEscherichai coliconfers susceptibility to oxazolidinone antibiotics” Abstracts of the Interscience Conference Of Antimicrobial Agents And Chemotherapy, vol. 36, No. 0, pp. 41. 36thICAAC (International Conference of Antimicrobial Agents and Chemotherapy) New Orleans, Louisiana, USA. Sep. 15-18.
Cohen, Seth P. et al. (1989) “Cross-Resistance to Fluoroquinolones In Multiple-Antibiotic-Resistant (Mar)Escherichia coliSelected By Tetracycline Or Chloramphenicol: Decreased Drug Accumulatin Associated With Membrane Changes In Addition To OmpF Reduction” Antimicrobial Agents and Chemotherapy, vol. 33, No. 8, pp. 1318-1325.
Fourner, B. et al. A mutation in griB Gene of topoisomerase IV fromStaphlococcus aureusCauses an Increase of Fluoroquinolone Resistance and A Decrease of coumarin Resistance, Abstracts of the 37thInterscience Conference on Antimicrobial Agents and Chemotherapy.
Goldman, John D. (1996) “Multiple Antibiotic Resistance (mar) Locus ProtectsEscherichia coliFrom Rapid Cell Killing by Fluoroquinolones” Antimicrobial Agents and Chemotherapy, vol. 40, No. 5, pp. 1266-1269.
Gustafson, John E. et al. (1999) “Growth In The Presence of Salicylate Increases Fluoroquinolone Resistance In Staphylococcus Aureus” Antimicrobial Agents and Chemotherapy, vol. 45, No. 4 pp. 990-992.
Hooper DC, et al. (1987) “Mechanisms of action of and resistance to ciprofloxacin”. Am J Med. 82(4A).
Hullen, V. et al. (1998) “Induction of the mar Phenotype Is a Possible Cause for The Development of Fluoroquinolone Resistance InEscherichia coli,” Antimicrob. Resist. Action.
Kern, W. V. et al. Selection of high-level fluoroquinolone-resistantEcherichia colimutants in-vitro:involvement of the mar or Sox system, Abstracts of the 37thInerscience Conference on Antimicrobial Agents and Chemotherapy.
Levy, Colin W et al. (1999) “Molecular Basis of Triclosan Activity” Nature, vol. 398, pp. 383-384.
Lewis, Kim et al. (1996) “Multidrug Resistance Pumps Provide Broad Defense” ASM News, vol. 63, No. 11 pp. 605-610.
Lewis, Kim (1994) “Multidrug Resistance Pumps In Bacteria; Variations On a Theme”TIBS 19, pp. 119-123.
Lomovskaya, O. et al. “Identification and characterization of Efflux Pump Inhibitors inP. aeruginosa”, Abstract No. F-1264, Poster Presentation at the 38thInerscience Conference on Antimicrobial Agents and Chemotherapy.
Lomovskaya, O. et al. “Inhibitors of Efflux Pumps inPseudomonas aeuruginosaPotentiate the Activity of the Flurorquinolone Antibacterial Levoflaxacin”, Abstract No. F-1265, Poster Presentation at the 38thInerscience Conference on Antimicrobial Agents and Chemotherapy.
Lomovskaya, O. et al. “Effux Pump Inhibitors (EPIs) Enhance the Activity of antrimicrobial Agents against a road Selection of Bacteria”, Abstract No. F-1266, Poster Presentation at the 38thInerscience Conference on Antimicrobial Agents and Chemotherapy.
Lomovskaya, O. et al. “Prevalence of Efflux Pump Overexpression Among Clinical Isolates of PseudomonEffux Pump Inhibitors (EPIs) Enhance the Activity of antrimicrobial Agents against a road Selection of Bacteria”, Abstact No. F-1267, Poster Presentation at the 38thInerscience Conference on Antimicrobial Agents and Chemotherapy.
Lomovskaya, O. et al. “Potentiation of Levoloxacin (Ievo) by a Broad-Spectrum Efflux Pump Inhibitor ('EPI) in Mouse Models of Infection Due to Pseudomanaaeurinasa”, Abstact No. F-1268, Poster Presentation at the 38thInerscience Conference on Antimicrobial Agents and Chemotherapy.
Lomovskaya, O. et al. “Inhibitors of Fungal Efflux Pump”, Abstact No. F-1269, Poster Presentation at the 38thInerscience Conference on Antimicrobial Agents and Chemotherapy.
Lomovskaya, Olga et al. (1999) “Use of a Genetic Approach To Evaluate the Consequences of Inhibition of Efflux Pumps inPseudomonas aeruginosa” Antimicrobial Agents and Chemotherapy, vol. 43, No. 6, pp. 1340-1346.
Markham PN, et al. (1999)Multiple novel inhibitors of the NorA multidrug transporter ofStaphylococcus aureus. Antimicrob Agents Chemother.;43(10):2404-8.
Ma, Dzwokai et al. (1995) “Genes acrA and acrB Encode A Stress-Induced Efflux System ofEscherichia Coli” Molecular Microbiology vol. 16, No. 1, pp. 45-55.
Ma, Dzwoka et al. (1996) “The Local Repressor AcrR Plays A Modulating Role In The Regulation of acrAB Genes ofEscherichia coliby Global Stress Signals” Molecular Microbiology, vol. 19, No. 1, pp. 101-112.
McMurry, Laura et al. (1998) Overexpression of marA, soxS, or acrAB produces resistance to triclosan inEscherichia coli: FEMS Microbiol. Lett. 166(2), 305-309.
McMurry, Laura et al. (1994) “Active Efflux of Chloramphenicol In SusceptibleEscherichia coliStrains and in Multiple-Antibiotic-Resistant (Mar) Mutants” Antimicrobial Agents and Chemotherapy, vol. 38, No. 3, pp. 542-546.
Miller, Paul F and Sulavik, Mark C. (1996) “Overlaps and Paralels In The Regulation of Intrinsic Multiple-Antibiotic Resistance InEscherichia coli” Molecular Microbiology, vol. 21, No. 3, pp. 441-448.
Moken, Merri C. et al. (1997) “Selectin of Multiple-Antibiotic-Resistant (Mar) Mutants ofEscherichia coliby Using the Disinfectant Pine Oil: Roles of the mar and acrAB Loci” Antimicrobial Agents and Chemotherapy vol. 41, No. 12, pp. 2770-2772.
Nikaido, Hiroshi (1996) “Multidrug Efflux Pumps of Gram-Neative Bacteria” Journal of Bacteriology vol. 178, No. 20 pp. 5853-5859.
Nikaido, Hiroshi et al. (1998) “Multidrug Efflux Pump AcrAB ofSalmonella typhimuriumExcretes Only Those β-Lactam Antibiotics Containing Lipophilic Side Chains” Journal of Bacteriology, vol. 180, No. 17, pp. 4686-4692.
Oethinger, M. et al., (1998) “Ineffectiveness of Topoisomerase Mutations inEscherichia coliin the Absence of the AcrAB Multidrug Efflux Pump” Preseented at the 38thInterscience Conference on Antimicrobial Agents and Chemotherapy; Sep. 24-27, 1998 in San Diego, CA. (Abstract No. C125).
Oethinger, Margret et al.
Levy Stuart B.
Oethinger Margaret
Hanley Elizabeth A.
Lahive & Cockfield
Leary Louise N.
Trustees of Tufts College
Williams Megan E.
LandOfFree
Methods of reducing microbial resistance to drugs does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of reducing microbial resistance to drugs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of reducing microbial resistance to drugs will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3598834